CORDIS
EU research results

CORDIS

English EN

WEB ACCESSIBLE MR DECISION SUPPORT SYSTEM FOR BRAIN TUMOUR DIAGNOSIS AND PROGNOSIS, INCORPORATING IN VIVO AND EX VIVO GENOMIC AND METABOLIMIC DATA

Project information

Grant agreement ID: 503094

  • Start date

    1 February 2004

  • End date

    31 July 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 9 496 336

  • EU contribution

    € 7 499 982

Coordinated by:

UNIVERSITAT DE VALENCIA - ESTUDI GENERAL

Spain

Objective

Diagnosis and treatment of brain tumours is based on clinical symptoms, radiological appearance, and often a histopathological diagnosis of a biopsy. However, treatment response of histological or radiologically similar tumours can vary widely, particularly for childhood tumours. New technologies are available that may improve tumour classification in terms of diagnosis and prognosis, and may allow individually optimised treatments.

Magnetic Resonance Spectroscopy (MRS) is a non-invasive technique for determining tissue biochemicals (the metabolomic profile). MRS can be performed along with clinical MR Imaging but widespread use is hampered by specialised analysis requirements and poor dissemination of the skills needed to interpret the data. The genomic profile of tumours can be determined with DNA microarrays. Early studies have demonstrated differences in gene expression between tumour grades and between tumour types not easily distinguished by morphologic appearance.

We will bring together the expertise required to study the genomic and metabolomic characteristics of brain tumours, with a multi-centre collaboration to acquire statistically significant data, particularly for rare tumour types. Clinical MRS, high-resolution 1H MRS and gene array analysis of biopsies, will be used to investigate how metabolomic and genomic profiles relate to clinically relevant factors such as survival time and treatment response. As well as providing new scientific data on tumour biology, we will develop the technology for this information to be readily and easily used to help radiologists and neurosurgeons in the management and treatment of brain tumour patients. We will build upon expertise obtained with INTERPRET EU project IST-1999-10310, which created a MRS decision support tool (DSS) for tumour diagnosis. A new web-accessible DSS will be developed, incorporating genomic and metabolomic data, and its diagnostic performance validated.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAT DE VALENCIA - ESTUDI GENERAL

Address

Avda. Blasco IbaÑEz, 13
Valencia

Spain

Participants (18)

BRUKER BIOSPIN SA.

France

DEUTSCHES KREBSFORSCHUNGSZENTRUM

Germany

FUNDACIÓN PARA LA LUCHA CONTRA ENFERMEDADES NEUROLÓGICAS DE LA INFANCIA

Argentina

HOSPITAL SANT JOAN DE DÉU

Spain

HYPERPHAR GROUP SPA

Italy

INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE

France

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

MEDICAL UNIVERSITY LODZ

Poland

MICROART, S.L.

Spain

PHARMA QUALITY EUROPE, S.R.L.

Italy

SCITO S.A.

France

SIEMENS AG, MEDICAL SOLUTIONS

Germany

ST GEORGE'S HOSPITAL MEDICAL SCHOOL'

United Kingdom

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

THE UNIVERSITY OF NOTTINGHAM

United Kingdom

UNIVERSIDAD POLITÉCNICA DE VALENCIA

Spain

UNIVERSITAT AUTÒNOMA DE BARCELONA

Spain

UNIVERSITY OF BIRMINGHAM

United Kingdom

Project information

Grant agreement ID: 503094

  • Start date

    1 February 2004

  • End date

    31 July 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 9 496 336

  • EU contribution

    € 7 499 982

Coordinated by:

UNIVERSITAT DE VALENCIA - ESTUDI GENERAL

Spain